This is a rare blood disorder where red blood cells break down in your blood vessels. This causes hemoglobin to leak into your urine, making it look pink or red. It can happen suddenly, sometimes triggered by cold or infection.
Every report comes from a Lived member, sent anonymously.
Have you tried Ultomiris (Ravulizumab) for Paroxysmal Hemoglobinuria?
Paroxysmal hemoglobinuria is a name shared by two rare blood conditions in which red blood cells burst inside the blood vessels, often in episodes (paroxysms). When that happens, hemoglobin, the oxygen-carrying protein inside red cells, spills into the blood and passes into the urine, turning it red, brown or cola-colored. The loss of red cells causes hemolytic anemia, a shortage of red blood cells because they are being destroyed, which can bring tiredness, weakness, paleness and breathlessness. The two conditions share a name and a sign but little else. Paroxysmal nocturnal hemoglobinuria (PNH), also called Marchiafava-Micheli syndrome, is a long-term bone marrow disorder that is usually diagnosed in young or middle adulthood. Its most serious danger is not the anemia but blood clots, which often form in unusual places such as the veins of the abdomen, liver or brain; in untreated PNH, clots are the leading cause of death. PNH can also lower white blood cell and platelet counts. Despite the name, many people with PNH never notice dark urine, while fatigue is very common. Paroxysmal cold hemoglobinuria (PCH) is an autoimmune anemia: the immune system makes an antibody that attacks red cells after the blood has been chilled. Today it mostly affects young children for a short time after a viral infection.
PNH begins when a blood-forming stem cell in the bone marrow acquires a change in a gene called PIGA during a person's lifetime. The blood cells descended from that stem cell lack a group of surface proteins that normally protect them from complement, a part of the immune system that destroys germs by damaging their outer membranes. Without that protection, complement destroys the red cells. Because the change arises in the marrow rather than being inherited, PNH does not run in families and is not passed to children (a very rare inflammatory form linked to a different gene is the exception). PNH is closely linked to aplastic anemia, a condition in which the marrow makes too few blood cells; about half of people with PNH have a history of it. Infections, inflammation, surgery and pregnancy all switch complement on and can set off a severe burst of hemolysis. PCH is caused by an antibody called the Donath-Landsteiner antibody. When blood cools, the antibody attaches to red cells; when the blood warms again, complement destroys them. In children it usually follows an upper respiratory infection or a stomach bug, typically around two weeks earlier, although some people have no recognized infection. In the past, PCH was mostly a chronic complication of syphilis in adults, and that form can still occur.
Both conditions are first recognized through blood and urine tests showing that red cells are being destroyed: anemia, a high count of young red cells (reticulocytes) as the marrow tries to keep up, a raised LDH (lactate dehydrogenase, an enzyme released from damaged cells), and hemoglobin in the urine. PNH is confirmed by flow cytometry, a blood test that checks red and white blood cells for the missing protective proteins. It also measures the clone size, the share of blood cells that are PNH cells. A larger clone generally means more active disease and a higher risk of clots, and clone size helps decide whether treatment is needed. Doctors look for PNH when hemolysis has no other explanation, when a clot appears in an unusual place, when blood counts are low or aplastic anemia is diagnosed, and when there are unexplained bouts of abdominal pain or difficulty swallowing alongside hemolysis. A bone marrow examination may be done to see how well the marrow is producing blood cells. PCH is confirmed with the Donath-Landsteiner test, which chills and then warms a blood sample to show the antibody at work. Few laboratories perform it, which can delay the diagnosis. A more common screening test, the direct antiglobulin (Coombs) test, often hints at PCH but can be misleading, so the Donath-Landsteiner test is worth doing when a child develops hemolysis after an infection, whatever that result shows.
For PNH, the main treatment is a complement inhibitor, a medicine that blocks the immune pathway destroying the red cells. Eculizumab (Soliris, also available as the biosimilars Bkemv and Epysqli) and ravulizumab (Ultomiris) block a complement protein called C5. They stop red cells from bursting inside blood vessels, and since their arrival clots have become far less common (about 92 percent fewer than before eculizumab) and survival has improved dramatically. Eculizumab is given as an IV infusion every 2 weeks; ravulizumab is given every 4 or 8 weeks, depending on body weight. On a C5 inhibitor, some people (roughly 10 to 30 percent) remain anemic and tired because their red cells are still cleared in the spleen and liver. Two newer medicines act earlier in the complement pathway and can raise hemoglobin in this situation: pegcetacoplan (Empaveli), infused under the skin twice a week, and iptacopan (Fabhalta), a capsule taken twice a day. Both are approved for adults with PNH, including as a first treatment. Not everyone with a PNH clone needs these drugs; when the clone is small and there are no symptoms of hemolysis, they may offer little benefit. All complement inhibitors carry one decisive trade-off: they raise the risk of rapidly life-threatening infection with meningococcal bacteria (a cause of meningitis and bloodstream infection) and, for some of these medicines, other bacteria such as pneumococcus. Vaccines are required at least 2 weeks before starting, or antibiotics are given if treatment cannot wait. Vaccination lowers but does not remove the risk, so people on these medicines carry a patient safety card describing warning signs. Other care includes blood transfusions when needed and blood thinners for people who have had a clot. Complement inhibitors do not fix low blood counts caused by bone marrow failure, which is treated separately. A stem cell (bone marrow) transplant is the only cure for PNH, but because of its serious risks, including graft-versus-host disease and death from complications, it is mostly reserved for severe marrow failure or disease that medicines cannot control. For PCH, care is supportive while the illness runs its course. Blood transfusion is often needed because hemoglobin can fall quickly to very low levels. Keeping the person warm is commonly tried. Corticosteroids are frequently given, but it is not clear that they help, and complement inhibitors have been used only in a handful of severe cases. When syphilis is the cause, treating the infection is part of care.
PNH is a long-term condition, but its outlook has changed greatly. Before complement inhibitors, about 30 percent of people died within 5 years, mostly from clots; with modern treatment, survival has improved dramatically. Treatment is usually lifelong, with regular infusions, injections or daily capsules. Keeping to the schedule matters, because protection can wear off and hemolysis can return; stopping a medicine is done only with close monitoring. Even on treatment, some people still feel tired or need occasional transfusions, and infections, surgery or pregnancy can trigger flares of hemolysis that may need a temporary change in dosing. Follow-up includes regular blood tests, a repeat flow cytometry check about every 6 months, and attention to kidney function, clots and bone marrow health. In a small number of people PNH fades on its own, while a few develop bone marrow failure or, rarely, leukemia. Pregnancy carries a high risk of clots and complications for both parent and baby, so it needs planning with a hematology team; eculizumab has been used during pregnancy with better outcomes in reported cases. PCH is usually short-lived. In recent reports, most cases resolved in about two weeks, and nearly everyone survived. The first days can be serious because anemia may deepen quickly, sometimes requiring a hospital stay and transfusions.
See a doctor if you notice red, brown or cola-colored urine, especially with tiredness, paleness or yellowing of the skin or eyes, or if you have unexplained anemia, low blood counts or a history of aplastic anemia. A child who has recently had a cold or stomach bug and then develops dark urine with sudden paleness or unusual tiredness should be seen the same day, since the anemia of PCH can worsen quickly. If you have PNH, contact your care team right away if you miss a dose, or if dark urine, fatigue or breathlessness return or worsen. Talk with them ahead of any planned pregnancy or surgery. Get emergency care for signs of a possible blood clot: sudden severe abdominal pain, a sudden severe headache, trouble speaking or weakness on one side of the body, chest pain or sudden shortness of breath, or a painful swollen leg. If you take a complement inhibitor, get emergency care right away for fever, fever with a rash, headache with fever or a stiff neck, confusion, or eyes that are sensitive to light, which can be early signs of meningococcal infection, and show your patient safety card.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Paroxysmal Hemoglobinuria is like, what's helped you, or ask the community a question.